Cargando…
Efficacy of infectious bronchitis virus vaccines against heterologous challenge
Twenty-four-week-old white Leghorn layers were inoculated subcutaneously with a killed Newcastle disease-infectious bronchitis (Massachusetts type) virus (mibv) vaccine. Twenty-eight weeks after vaccination, the birds were challenged intraocularly with the Arkansas strain of infectious bronchitis vi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
1988
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131188/ https://www.ncbi.nlm.nih.gov/pubmed/2851866 http://dx.doi.org/10.1016/S0034-5288(18)30889-0 |
_version_ | 1783517181679501312 |
---|---|
author | MUNEER, M.A. NEWMAN, J.A. HALVORSON, D.A. SIVANANDAN, V. NAGARAJA, K.V. COON, C.N. |
author_facet | MUNEER, M.A. NEWMAN, J.A. HALVORSON, D.A. SIVANANDAN, V. NAGARAJA, K.V. COON, C.N. |
author_sort | MUNEER, M.A. |
collection | PubMed |
description | Twenty-four-week-old white Leghorn layers were inoculated subcutaneously with a killed Newcastle disease-infectious bronchitis (Massachusetts type) virus (mibv) vaccine. Twenty-eight weeks after vaccination, the birds were challenged intraocularly with the Arkansas strain of infectious bronchitis virus (aibv) to determine the effects of heterologous virus exposure on egg production, egg quality and serum antibody response of the birds. The challenged hens laid significantly (P<0·005) fewer eggs than the unchallenged layers. Eggs laid by the unchallenged groups weighed significantly more (P<0·005) than those laid by the challenged groups. Further, the internal quality (Haugh units) and shell quality of eggs laid by the aibv-challenged hens was significantly (P<0·005) inferior to those from the unchallenged hens. In addition, the aibv-challenged hens laid more soft-shell, misshapen and small eggs than the unchallenged hens. The Arkansas serum haemagglutination inhibition (aibv-hi) titres of aibv challenged birds increased up to four weeks after challenge. The corresponding mibv haemagglutination-inhibition (mibv-hi) titres decreased during the same period. The study indicates that killed mibv vaccine offered no protection to birds exposed to heterologous aibv. |
format | Online Article Text |
id | pubmed-7131188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1988 |
publisher | Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71311882020-04-08 Efficacy of infectious bronchitis virus vaccines against heterologous challenge MUNEER, M.A. NEWMAN, J.A. HALVORSON, D.A. SIVANANDAN, V. NAGARAJA, K.V. COON, C.N. Res Vet Sci Article Twenty-four-week-old white Leghorn layers were inoculated subcutaneously with a killed Newcastle disease-infectious bronchitis (Massachusetts type) virus (mibv) vaccine. Twenty-eight weeks after vaccination, the birds were challenged intraocularly with the Arkansas strain of infectious bronchitis virus (aibv) to determine the effects of heterologous virus exposure on egg production, egg quality and serum antibody response of the birds. The challenged hens laid significantly (P<0·005) fewer eggs than the unchallenged layers. Eggs laid by the unchallenged groups weighed significantly more (P<0·005) than those laid by the challenged groups. Further, the internal quality (Haugh units) and shell quality of eggs laid by the aibv-challenged hens was significantly (P<0·005) inferior to those from the unchallenged hens. In addition, the aibv-challenged hens laid more soft-shell, misshapen and small eggs than the unchallenged hens. The Arkansas serum haemagglutination inhibition (aibv-hi) titres of aibv challenged birds increased up to four weeks after challenge. The corresponding mibv haemagglutination-inhibition (mibv-hi) titres decreased during the same period. The study indicates that killed mibv vaccine offered no protection to birds exposed to heterologous aibv. Published by Elsevier Ltd. 1988-07 2018-08-23 /pmc/articles/PMC7131188/ /pubmed/2851866 http://dx.doi.org/10.1016/S0034-5288(18)30889-0 Text en Copyright © 1988 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article MUNEER, M.A. NEWMAN, J.A. HALVORSON, D.A. SIVANANDAN, V. NAGARAJA, K.V. COON, C.N. Efficacy of infectious bronchitis virus vaccines against heterologous challenge |
title | Efficacy of infectious bronchitis virus vaccines against heterologous challenge |
title_full | Efficacy of infectious bronchitis virus vaccines against heterologous challenge |
title_fullStr | Efficacy of infectious bronchitis virus vaccines against heterologous challenge |
title_full_unstemmed | Efficacy of infectious bronchitis virus vaccines against heterologous challenge |
title_short | Efficacy of infectious bronchitis virus vaccines against heterologous challenge |
title_sort | efficacy of infectious bronchitis virus vaccines against heterologous challenge |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131188/ https://www.ncbi.nlm.nih.gov/pubmed/2851866 http://dx.doi.org/10.1016/S0034-5288(18)30889-0 |
work_keys_str_mv | AT muneerma efficacyofinfectiousbronchitisvirusvaccinesagainstheterologouschallenge AT newmanja efficacyofinfectiousbronchitisvirusvaccinesagainstheterologouschallenge AT halvorsonda efficacyofinfectiousbronchitisvirusvaccinesagainstheterologouschallenge AT sivanandanv efficacyofinfectiousbronchitisvirusvaccinesagainstheterologouschallenge AT nagarajakv efficacyofinfectiousbronchitisvirusvaccinesagainstheterologouschallenge AT cooncn efficacyofinfectiousbronchitisvirusvaccinesagainstheterologouschallenge |